Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,043,339,390.90, representing a 24.87% increase compared to CNY 835,528,794.61 in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was CNY 273,059,845.78, a 56.18% increase from CNY 174,835,885.10 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 273,092,726.63, reflecting a 67.97% increase from CNY 162,586,812.07 in the same period last year[17]. - The basic earnings per share for the first half of 2023 was CNY 0.6382, up 56.19% from CNY 0.4086 in the previous year[17]. - The diluted earnings per share for the first half of 2023 was CNY 0.6349, an increase of 55.38% compared to CNY 0.4086 in the same period last year[17]. - The company's revenue for the first half of 2023 showed steady growth, with net profit attributable to shareholders significantly increasing, aligning with the company's initial plans[35]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a 25% year-over-year growth[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a year-over-year growth of 20%[49]. Research and Development - The company's R&D expenses accounted for nearly 20% of its operating revenue during the reporting period[2]. - The company is focused on the development of new products and technologies to enhance its market position[2]. - The company is committed to continuous R&D investment to maintain its competitive edge and respond quickly to market demands[34]. - The company has over 600 R&D personnel, with more than 40% holding master's degrees or higher, and has received multiple national and provincial recognitions for its innovation capabilities[61]. - R&D expenses for 2020, 2021, and 2022 were CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million, representing 20.41%, 18.21%, and 18.66% of total revenue respectively[61]. - The company is investing in R&D for advanced imaging technologies, with a budget allocation of 200 million RMB for 2023, aiming to innovate and expand its product line[48]. Market Position and Strategy - The medical device market is highly competitive, with numerous participants, and the company must maintain its competitive advantages to avoid market elimination[3]. - The company has established a strong competitive advantage in the international medical device market, particularly in ultrasound and endoscope sectors[25]. - The company continues to focus on expanding its product offerings and market presence, particularly in the ultrasound diagnostic equipment sector[17]. - The company aims to contribute to the rise of domestic medical devices by developing high-end medical equipment with independent intellectual property rights[25]. - The company is focusing on expanding its multi-product strategy, transitioning from diagnostic to "diagnostic + treatment" solutions[32]. - The company is actively pursuing new strategies for market expansion, leveraging its innovative product pipeline to capture growth opportunities in the medical device sector[41][42]. Product Development and Innovation - The company has developed a comprehensive range of ultrasound products, including high-end, mid-range, and low-end devices, meeting diverse clinical application needs across various fields[27]. - The high-end ultrasound products S60 and P60 series have received high recognition from experts in top-tier hospitals, particularly excelling in obstetrics and gynecology compared to imported counterparts[27]. - The company has successfully obtained NMPA Class III medical device registration for its intravascular ultrasound diagnostic equipment and disposable intravascular ultrasound diagnostic catheters, becoming the only domestic ultrasound manufacturer with such capabilities[31]. - The new ultra-high-end ultrasound platform received CE (MDR) certification in December 2022, expected to enhance market competitiveness and brand influence upon launch[27]. - The company has expanded its product line in the endoscope sector, including HD350, HD400, HD500, and HD550 series, covering high, mid, and low-end markets[28]. - The introduction of the SFI imaging technology and the combination with the HD-550 system provides a complete solution for early diagnosis and treatment of diseases[28]. - The company has launched the ProPet series for veterinary ultrasound applications, further broadening its ultrasound product market[32]. - The company’s ultrasound products have achieved significant advancements, with a complete range of high, mid, and low-end products developed over 20 years[32]. Financial Position - Total assets at the end of the reporting period were CNY 3,692,742,172.90, a 4.19% increase from CNY 3,544,216,145.59 at the end of the previous year[17]. - The net assets attributable to shareholders at the end of the reporting period were CNY 3,000,049,043.36, reflecting a 9.50% increase from CNY 2,739,802,619.18 at the end of the previous year[17]. - The weighted average return on equity for the first half of 2023 was 9.48%, an increase of 2.37% from 7.11% in the previous year[17]. - The company's gross profit margin has improved due to an increase in the proportion of high-end products sold, while the ratio of operating expenses to revenue has decreased[37]. - The company reported a total investment of ¥27,630,500.99 during the reporting period, a decrease of 32.51% from ¥40,941,025.43 in the same period last year[79]. - The company has ongoing major non-equity investments, including the construction of a medical device industrial base with an investment of ¥1,139,899.51, which is 98.46% complete[81]. Risks and Challenges - The company faces risks related to overseas sales, including currency fluctuations and geopolitical tensions, which could adversely affect its international business[2]. - The company acknowledges the potential impact of healthcare policy changes on market pricing and procurement processes[4]. - The company continues to face various risks, with specific measures outlined in the report[101]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[112]. - The company has not engaged in any major related party transactions during the reporting period[114]. Corporate Governance and Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares[6]. - The annual general meeting held on May 10, 2023, had an investor participation rate of 57.44%[105]. - The company has not encountered any issues regarding the use and disclosure of raised funds[88]. - The company has not made any capital increases from capital reserves during the reporting period[106]. - The company has no significant changes in the conditions affecting the performance of contracts during the reporting period[118]. - The company has no major risks of contract non-performance during the reporting period[118].

深圳开立生物医疗科技股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 募集资金基本情况 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会证监许可〔2021〕668 号文核准，并经深圳证券 交易所同意，本深圳开立生物医疗科技股份有限公司（以下简称"公司"）由主 承销商长城证券股份有限公司（以下简称"长城证券"）采用定向发行方式，向 特定对象非公开发行股份人民币普通股（A 股）股票 27,851,745 股，发行价为每 股人民币 27.79 元，共计募集资金 773,999,993.55 元，坐扣承销费用 1,886,792.45 元后的募集资金为 772,113,201.10 元，其中 245,167,501.10 元已由长城证券于 2021 年 12 月 21 日汇入公司在中国工商银行股份有限公司南山支行开立的账号 为 4000020319200789913 的人民币账户，526,945,700.00 元已由长城证券于 2021 年 12 月 21 日汇入公司在汇丰银行(中国)有 ...

深圳开立生物医疗科技股份有限公司 2023 年限制性股票激励计划激励对象名单 | | | 获授的限制性 | 占本激励计划授予 | 占目前总 | | --- | --- | --- | --- | --- | | 人员 | 国籍 | 股票数量 | 限制性股票总数的 | 股本的比 | | | | （股） | 比例 | 例 | | YANG MEI | 加拿大 | 1,597,000 | 48.48% | 0.37% | | Helga Schemm | 德国 | 107,100 | 3.25% | 0.02% | | 微创外科业务团队员工及董事 会认为应当激励的其他人员 | 中国 | 1,589,900 | 48.27% | 0.37% | | （共 32 人） | | | | | | 合计 | | 3,294,000 | 100.00% | 0.76% | 一、限制性股票激励计划分配情况表 注：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致，下同。 二、微创外科业务团队员工及董事会认为应当激励的其他人员名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-041 深圳开立生物医疗科技股份有限公司 第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2023 年 8 月 21 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第三届监事会第十三次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过了如下决议： 1、审议通过《关于公司 2023 年半年度报告及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2023 年半年度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网披 露的《2023 年半年度报告》以及《2023 年半 ...

证券代码：300633 证券简称：开立医疗 编号：2023-009 深圳开立生物医疗科技股份有限公司 2023 年 7 月 13-14 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|--------------| | | 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | □ 一对一沟通 | | | 电话会议 | □ 其他 | 兴业证券、建信基金、富荣基金、中融基金、康曼德资本、睿远基 金、先锋基金、中欧瑞博、前海联合基金、基石资本、石智（泉 州）基金、鸿昇金融集团、广东乐赢、上汽颀臻、相聚资本、国信 参与单位 名称 证券投资总部、创金合信基金、景顺基金、惠升基金、平安医药、 兴证医药、东吴医药、华夏基金、民生医药、华商基金、华安基 金、广发基金 时间 2023 年 7 月 13-14 日 地点 公司会议室 上市公司 接待人员 董事会秘书李浩、证券事务代表吴坚志 问：公司 2023 年半年度净利润增速较好的原因？ ...

证券代码：300633 证券简称：开立医疗 编号：2023-008 深圳开立生物医疗科技股份有限公司 2023 年 5 月 15-26 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|--------------| | | 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | □ 一对一沟通 | | | 电话会议 | □ 其他 | 崇山投资、申万宏源、香港盈科、嘉合基金、易方达基金、中庸资 产、世豪资本、华安证券、乐中控股、珠海乐中、长青藤、诚诺资 产、光大证券、兴合基金、兰馨亚洲基金、高盛资管、花旗银行、 参与单位 名称 万利富达、招商资管、东莞证券、财信证券、华创证券、安信资 管、景顺长城基金、汇添富基金、财通基金、国华兴益保险资产、 华福证券、工银瑞信、华金证券、国联证券、开源证券 时间 2023 年 5 月 15-26 日投资者关系活动记录表 地点 公司会议室 上市公司 接待人员 董事长陈志强、董事会秘书李浩、 ...

证券代码：300633 证券简称：开立医疗 编号：2023-007 深圳开立生物医疗科技股份有限公司 2023 年 5 月 10-11 日投资者关系活动记录表 | --- | --- | --- | |------------|--------------|------------| | | 特定对象调研 | 分析师会议 | | 投资者关 | □ 媒体采访 | 业绩说明会 | | 系活动类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | 一对一沟通 | | | □ 电话会议 | 其他 | 华夏基金、彤源投资、世豪资本、连捷投资、怀德资本、方正证券 医药、南方基金、富荣基金、森瑞投资、国信医药、正奇资本、东 参与单位 名称 方合盈、深圳诚诺资产、东方睿信基金、千榕资产、华泰医药、申 万宏源医药、丹麓资本、红筹投资、德摩资本、石智基金、珠海乐 中投资、光大证券医药、上海理成资产、上海沣杨资产、鑫鼎基金 时间 2023 年 5 月 10-11 日投资者关系活动记录表 地点 公司会议室 上市公司 接待人员 董事长陈志强、董事会秘书李浩、财务总监罗曰佐 问：日本内窥镜企业在国内设立工厂，公司如何看待？ ...

Financial Performance - The company's revenue for Q1 2023 was CNY 473,030,518.35, representing a 27.63% increase compared to CNY 370,629,245.42 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 138,474,386.29, a significant increase of 171.11% from CNY 51,076,948.02 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 125,533,224.91, up 157.67% from CNY 48,718,416.30 year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.3236, an increase of 171.02% compared to CNY 0.1194 in the same period last year[10] - Total operating revenue for Q1 2023 reached ¥473,030,518.35, an increase of 27.7% compared to ¥370,629,245.42 in Q1 2022[19] - Operating profit for Q1 2023 was ¥149,428,037.24, up 165.7% from ¥56,213,208.39 in the same period last year[19] - Net profit attributable to the parent company for Q1 2023 was ¥138,474,386.29, a significant increase from ¥51,076,948.02 in Q1 2022, representing a growth of 171.5%[20] - Basic earnings per share for Q1 2023 were ¥0.3236, compared to ¥0.1194 in Q1 2022, reflecting a 171.5% increase[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,692,458,938.45, reflecting a 4.18% increase from CNY 3,544,216,145.59 at the end of the previous year[5] - The total current assets amounted to ¥2,633,566,082.40, up from ¥2,514,310,007.04, indicating an increase of about 4.7%[15] - The total assets of the company reached ¥3,692,458,938.45, compared to ¥3,544,216,145.59 at the beginning of the year, reflecting a growth of approximately 4.2%[16] - The total liabilities decreased to ¥762,787,304.45 from ¥804,413,526.41, a reduction of approximately 5.2%[17] - Total equity attributable to shareholders increased to ¥2,929,671,634.00 from ¥2,739,802,619.18, marking a growth of 6.9%[17] Cash Flow - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 148,591,670.00, which is a 50.16% increase from CNY 98,957,000.00 year-on-year[10] - The net cash flow from operating activities for Q1 2023 was CNY 48,269,069.80, a decrease of 7.21% compared to CNY 52,021,509.15 in the same period last year[5] - Cash generated from operating activities was ¥509,891,004.68, compared to ¥459,218,493.82 in the previous year, indicating an increase of 11.1%[21] - The net cash flow from operating activities for Q1 2023 was ¥48,269,069.80, a decrease of 1.44% compared to ¥52,021,509.15 in Q1 2022[22] - The total cash and cash equivalents at the end of Q1 2023 reached ¥1,485,916,653.31, up from ¥989,579,920.30 at the end of Q1 2022, representing a significant increase of 50.3%[23] Expenses - The company experienced a 44.05% increase in selling expenses, totaling CNY 10,568,180.00, primarily due to increased human resources and travel costs[9] - The company’s financial expenses decreased by 464.05% to -CNY 730,460.00, mainly due to increased interest income[9] - Research and development expenses for Q1 2023 were ¥80,009,904.74, up from ¥75,702,238.74 in Q1 2022, reflecting a growth of 5.4%[19] - Sales expenses increased to ¥105,681,831.55 from ¥73,365,183.75, a rise of 43.9% year-over-year[19] - Cash paid for purchasing goods and services was ¥194,127,831.33, an increase of 22.47% compared to ¥158,565,395.48 in Q1 2022[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,518[11] - The largest shareholder, Chen Zhiqiang, holds 22.37% of the shares, totaling 95,725,200 shares, with 11,500,000 shares pledged[12] Other Information - The company reported a total of CNY 12,941,161.38 in non-recurring gains and losses for Q1 2023[6] - The company did not conduct an audit for the Q1 2023 report[24]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15% compared to 2021[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[76]. - The company achieved a total revenue of 1,762.649 million yuan in 2022, representing a year-on-year growth of 22.02%[49]. - The revenue from the ultrasound product line was ¥1,079,527,925.32, accounting for 61.24% of total revenue, with a growth of 14.14% from ¥945,800,908.14 in 2021[56]. - The revenue from endoscopes and related treatment instruments increased by 42.98% to ¥611,598,329.82, representing 34.70% of total revenue[56]. - The company reported a net profit of 300 million RMB for 2022, reflecting a growth of 20% compared to the previous year[13]. - Net profit attributable to shareholders for 2022 was ¥369,811,713.74, a 49.57% increase from ¥247,244,612.13 in 2021[19]. - The gross profit margin for 2022 was 45%, which is a slight improvement from 43% in the previous year[13]. - The company reported a gross margin of 60%, maintaining a stable margin despite rising raw material costs[76]. - The company reported a significant increase in trading financial assets to CNY 419.45 million, accounting for 11.83% of total assets, due to increased purchases of financial products[92]. Research and Development - The company's R&D expenses accounted for approximately 20% of its operating revenue in recent years, indicating a strong commitment to innovation despite inherent risks in product development[2]. - The company invested in R&D with expenditures of CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million for the years 2020, 2021, and 2022, respectively, representing 20.41%, 18.21%, and 18.66% of total revenue[41]. - The company has a dedicated R&D team of 631 personnel, accounting for 27.04% of total employees, ensuring a strong focus on product development[43]. - The company has developed advanced ultrasound technologies, including high-frequency probe technology and AI image recognition, positioning itself as a leader in the ultrasound field[40]. - The company launched the world's first AI-based dynamic image technology for prenatal ultrasound screening, enhancing efficiency in obstetric examinations[30]. - The company is focusing on improving customer service and support processes, which has led to increased customer satisfaction and repeat purchases[48]. - The company is committed to ongoing research and development to maintain its competitive edge in the medical technology sector[79]. Market Expansion - The company is expanding its market presence in Europe, with plans to establish a new distribution center in Germany by mid-2023[13]. - The company is actively pursuing market expansion and product innovation to enhance its competitive position in the medical device sector[67]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2023[112]. - The company has established a global marketing network covering nearly 130 countries and regions, enhancing its brand promotion and distributor training capabilities[43]. - The company is committed to localizing its operations in developed markets while refining its approach in developing markets, resulting in rapid business growth in regions like the US, Germany, and India[53]. Product Development - The company plans to launch three new ultrasound products in 2023, aiming to capture a larger market share in the medical imaging sector[13]. - The company has launched new products, including the P12 Elite and P20 Elite series ultrasound diagnostic systems, which were registered on September 15 and September 13, 2022, respectively[84]. - The company has introduced several new products in the endoscope field, including ultra-thin electronic gastroscopes and electronic colonoscopes, significantly enriching its product offerings and supporting market penetration[50]. - The company has launched the ProPet series of veterinary ultrasound products in 2022, expanding its market reach in ultrasound applications[35]. - The company has developed a unique competitive advantage in the hard endoscope field by integrating hard endoscopes with ultrasound systems[32]. Regulatory Compliance - The company is subject to significant regulatory risks due to the medical device industry's heavy government oversight, which could impact pricing and market dynamics[5]. - The company has received multiple certifications, including NMPA, FDA, and CE, ensuring compliance with international quality standards for its medical devices[44]. - The company has maintained compliance with internal control standards, ensuring the accuracy and completeness of financial reporting[160]. - The company has not reported any violations regarding external guarantees during the reporting period[171]. Corporate Governance - The board of directors held five meetings during the reporting period to ensure effective governance and decision-making[113]. - The company has established a comprehensive performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring competitive compensation[119]. - The company has a robust governance structure with independent directors who bring diverse expertise, including legal and engineering backgrounds[131]. - The company is committed to protecting the legal rights of shareholders through effective governance practices[142]. Financial Management - The company reported a total cash outflow from operating activities of CNY 1,663,498,449.80, which is a 16.82% increase from CNY 1,423,986,369.23 in the previous year[88]. - The net cash flow from operating activities reached ¥473,255,552.95, up 56.20% from ¥302,989,915.92 in 2021[19]. - The total amount of funds raised in 2021 was CNY 769,055,967.35 after deducting issuance costs, with no funds utilized as of the reporting period[100]. - The company has committed to invest CNY 24,705.43 million in the development of color ultrasound and endoscope products, with a cumulative investment of CNY 24,321.31 million, achieving 100.46% of the planned progress[102]. Strategic Initiatives - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 100 million RMB for 2023[112]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies specializing in diagnostic imaging technologies[76]. - The company completed a strategic acquisition of a smaller biotech firm for 500 million RMB to enhance its product portfolio[112]. - The company has implemented a training program focused on team capability development, emphasizing a "people-oriented, technology innovation" philosophy[150].

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）定于 2023 年 4 月 18 日（星期二）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会， 本次年度业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资 者关系互动平台"（http://ir.p5w.net）参与互动交流。 出席本次年度网上业绩说明会的人员包括：公司董事长陈志强先生、董事 会秘书李浩先生、财务总监罗曰佐先生、独立董事华小宁先生、保荐代表人郭 小元先生。 证券代码：300633 证券简称：开立医疗 公告编号：2023-015 深圳开立生物医疗科技股份有限公司 为做好中小投资者保护工作，增进投资者对公司的了解和认同，以提升公 司治理水平和企业整体价值，现就公司 2022 年度网上业绩说明会提前向投资者 征集相关问题，投资者可于 2023 年 4 月 17 日（星期一）17:00 前将有关问题通 过电子邮件的形式发送至公司投资者关系互动邮箱：ir@sonoscape.n ...